​

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MDGL Stock Forecast

Madrigal Pharmaceuticals (MDGL) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $673.38, with a high of $900.00 and a low of $527.00. This represents a 34.90% increase from the last price of $499.17.

$200 $340 $480 $620 $760 $900 High: $900 Avg: $673.38 Low: $527 Last Closed Price: $499.17

MDGL Stock Rating

Madrigal Pharmaceuticals stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (86.96%), 2 Hold (8.70%), 1 Sell (4.35%), and 0 Strong Sell (0.00%).

Buy
Total 23 1 2 20 0 Strong Sell Sell Hold Buy Strong Buy

MDGL Price Target Upside V Benchmarks

TypeNameUpside
StockMadrigal Pharmaceuticals34.90%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2812
Avg Price Target$575.00$673.38$626.42
Last Closing Price$499.17$499.17$499.17
Upside/Downside15.19%34.90%25.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 262131--16
Dec, 252131--16
Nov, 253102-116
Oct, 25391-114
Sep, 252111-115
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 14, 2026Andrea TanGoldman Sachs$571.00$493.9015.61%14.39%
Jan 06, 2026Andy ChenWolfe Research$579.00$588.40-1.60%15.99%
Dec 19, 2025Yasmeen RahimiPiper Sandler$900.00$588.8152.85%80.30%
Dec 19, 2025UBS$900.00$544.4165.32%80.30%
Nov 21, 2025H.C. Wainwright$620.00$558.6110.99%24.21%
Nov 20, 2025Jay OlsonOppenheimer$650.00$568.0214.43%30.22%
Nov 19, 2025Truist Financial$640.00$555.6015.19%28.21%
Nov 05, 2025JMP Securities$527.00$444.6418.52%5.58%
Oct 15, 2025Piper Sandler$540.00$437.1023.54%8.18%
Oct 14, 2025Truist Financial$580.00$437.1032.69%16.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 20, 2026CitigroupOutperformOutperformhold
Jan 14, 2026Goldman SachsBuyBuyhold
Jan 12, 2026Cowen & Co.BuyBuyhold
Jan 06, 2026Wolfe ResearchOutperformPeer Performdowngrade
Dec 19, 2025Piper SandlerOverweightOverweighthold
Dec 11, 2025B. RileyBuyBuyhold
Nov 21, 2025H.C. WainwrightBuyBuyhold
Nov 20, 2025OppenheimerOutperformOutperformhold
Nov 05, 2025CitigroupOutperformOutperformhold
Nov 04, 2025Cantor FitzgeraldNeutralOverweightupgrade

Financial Forecast

EPS Forecast

$-50 $-20 $10 $40 $70 $100 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.99$-21.90----
Avg Forecast$-19.44$-23.62$-12.97$2.87$32.05$57.26
High Forecast$-18.30$-22.60$-3.19$9.94$46.90$75.38
Low Forecast$-20.11$-24.76$-22.28$-4.22$7.13$34.14
Surprise %2.83%-7.28%----

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$180.13M----
Avg Forecast-$172.04M$514.95M$1.02B$1.88B$2.92B
High Forecast-$182.74M$633.56M$1.02B$1.94B$3.64B
Low Forecast-$161.27M$412.06M$1.02B$1.82B$2.02B
Surprise %-4.71%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-373.63M$-465.89M----
Avg Forecast$-373.63M$-442.50M$-297.44M$117.58M$782.67M$1.07B
High Forecast$-342.06M$-422.26M$-59.61M$185.69M$876.45M$1.41B
Low Forecast$-375.85M$-462.74M$-416.30M$-78.80M$133.33M$637.91M
Surprise %-5.29%----

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals stock a buy?

Madrigal Pharmaceuticals stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Madrigal Pharmaceuticals is a favorable investment for most analysts.

What is Madrigal Pharmaceuticals's price target?

Madrigal Pharmaceuticals's price target, set by 23 Wall Street analysts, averages $673.38 over the next 12 months. The price target range spans from $527 at the low end to $900 at the high end, suggesting a potential 34.90% change from the previous closing price of $499.17.

How does Madrigal Pharmaceuticals stock forecast compare to its benchmarks?

Madrigal Pharmaceuticals's stock forecast shows a 34.90% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Madrigal Pharmaceuticals over the past three months?

  • January 2026: 12.50% Strong Buy, 81.25% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 12.50% Strong Buy, 81.25% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 18.75% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.

What is Madrigal Pharmaceuticals’s EPS forecast?

Madrigal Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-12.97, marking a -40.78% decrease from the reported $-21.9 in 2024. Estimates for the following years are $2.87 in 2026, $32.05 in 2027, and $57.26 in 2028.

What is Madrigal Pharmaceuticals’s revenue forecast?

Madrigal Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $514.95M, reflecting a 185.87% increase from the reported $180.13M in 2024. The forecast for 2026 is $1.02B, followed by $1.88B for 2027, and $2.92B for 2028.

What is Madrigal Pharmaceuticals’s net income forecast?

Madrigal Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-297M, representing a -36.16% decrease from the reported $-466M in 2024. Projections indicate $117.58M in 2026, $782.67M in 2027, and $1.07B in 2028.